- PetVivo has entered into a merger agreement to acquire functional biomaterials developer PiezoBioMembrane (PBM).
- PBM will become a wholly owned subsidiary of Cosmeta Corp., PetVivo’s biomaterials and regenerative medicine division.
- The acquisition adds proprietary technologies, patents, trade secrets, regulatory assets, and development programs to PetVivo’s portfolio.
- Company leaders say the combined platform could support future medical device and therapeutic products across animal and human healthcare.
- The deal includes milestone-based incentives designed to align long-term value creation and development progress.
- Closing remains subject to due diligence, financing, and customary transaction conditions.
PetVivo Holdings has announced plans to acquire PiezoBioMembrane (PBM), a developer of advanced functional biomaterials and piezoelectric technologies, in a transaction the company says will strengthen its intellectual property portfolio and create new opportunities for product development across veterinary and human health markets.
Under the agreement, PBM will become a wholly owned subsidiary of Cosmeta Corp., PetVivo’s operating division focused on biomaterials, regenerative medicine technologies, and intellectual property commercialization.
The acquisition will provide PetVivo with access to PBM’s technology platform, including proprietary know-how, patents, patent applications, trade secrets, biomaterial formulations, manufacturing assets, regulatory information, and development programs supporting medical device and therapeutic innovation.
Building a Broader Biomaterials Platform
PetVivo CEO John Lai described the transaction as a significant step in the company’s long-term growth strategy.
According to Lai, combining PBM’s scientific capabilities with PetVivo’s product development, regulatory, manufacturing, and commercialization expertise could accelerate the advancement of technologies with applications in both animal and human healthcare.
The company also believes the expanded platform could create opportunities for future grant funding, research collaborations, and research and development tax credit programs that support innovation and product development efforts.
Under the terms of the merger agreement, PBM shareholders will receive a total of 3 million shares of PetVivo common stock. A portion of the consideration is tied to milestone-based retention and forfeiture provisions linked to development and regulatory achievements.
Focus on Regenerative Medicine and Medical Devices
PBM’s technology platform is centered on functional biomaterials designed to support tissue repair, regeneration, and other therapeutic applications. Company officials said combining the resources of PBM, Cosmeta, and PetVivo could help accelerate product development, regulatory advancement, strategic partnerships, and commercialization initiatives.
PBM President Thanh Nguyen said the transaction reflects years of scientific development and positions the technology platform for broader growth opportunities.
The agreement also provides a framework for continued involvement of key PBM personnel following the transaction, helping support technology development and milestone achievement after closing.
Supporting Future Product Development
PetVivo currently markets SPRYNG® with OsteoCushion® technology, an intra-articular injection used to manage lameness and joint-related conditions, including osteoarthritis, in dogs, cats, and horses. The company also commercializes PrecisePRP®, an off-the-shelf platelet-rich plasma product for veterinary use.
Company leaders said the addition of PBM’s technologies supports their broader strategy of leveraging biomaterials and regenerative medicine innovations to expand future product opportunities across multiple healthcare markets.
The transaction remains subject to customary closing conditions, including due diligence, financing activities, execution of related agreements, and other regulatory and transactional requirements.
Information sourced from the company’s press release.
